KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 17654 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Acute skin toxicity and cosmesis outcome in non-metastatic breast cancer patients treated with ultrahypofractionated radiotherapy: a randomized controlled phase II clinical trial comparing proton versus photon radiotherapy. PMID 42183732 · J Radiat Res · 2026-Jul-24 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Reduced breakthrough symptom exacerbations in patients with biochemically controlled acromegaly switched from injected depot somatostatin receptor ligands to once-daily oral paltusotine in the PATHFNDR-1 clinical trial. PMID 42493688 · Pituitary · 2026-Jul-23 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Re: Kitamura H, Tsukamoto T, Kakehi Y, et al. Active Surveillance Versus Intravesical Bacillus Calmette-Guérin for High-grade T1 Bladder Cancer with Negative Second Transurethral Resection: The Randomized Noninferiority Phase 3 JCOG1019 Trial. Eur Urol 2026;89:437-45. PMID 42493340 · Eur Urol · 2026-Jul-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Re: James P. Buteau, Daniel Moon, Michael T. Fahey, et al. Effect of [68Ga]Ga-PSMA-11 PET-CT in the Diagnosis of Prostate Cancer in Men with Equivocal or Clinically High-risk Non-suspicious Findings on Multiparametric MRI (PRIMARY2): A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Trial. Lancet Oncol 2026;27:839-848. PMID 42493339 · Eur Urol · 2026-Jul-23 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized phase II trial of nivolumab and ipilimumab with or without stereotactic body radiation therapy in patients with metastatic castration-resistant prostate cancer: the CheckPRO, CA209-8TY trial. PMID 42493213 · J Immunother Cancer · 2026-Jul-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Exploring the Feasibility, Acceptability, and Safety of a 4:3 Intermittent Fasting Weight Loss Program Among Stage I-III Breast Cancer Survivors With Overweight or Obesity: Protocol for a 6-Month Proof-of-Concept Feasibility Trial. PMID 42492498 · JMIR Res Protoc · 2026-Jul-23 This is a protocol for a proof-of-concept feasibility trial investigating a behavioral weight-loss intervention (intermittent fasting and exercise) among breast cancer survivors. It is not a randomized Phase III trial, does not involve a drug intervention, and does not report time-to-event efficacy outcomes.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Hypo- Versus Standard Fractionated Locoregional Radiotherapy of Patients With High-Risk Breast Cancer in the Randomized Phase III Trial: The Danish Breast Cancer Group Skagen Trial 1. PMID 42492022 · J Clin Oncol · 2026-Jul-23 Trial compares two radiotherapy fractionation schedules (drug-free intervention), not a drug-containing regimen. Meets all other criteria (Phase III, randomized, human oncology, time-to-event efficacy endpoints with original results) but fails the drug intervention requirement.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Sirexatamab in Combination with Bevacizumab and Chemotherapy as Second-Line Therapy for Advanced Colorectal Adenocarcinoma: the Phase II DeFianCe Trial. PMID 42489705 · Clin Cancer Res · 2026-Jul-23 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Robotic Thoracic Surgery After Neoadjuvant Chemo-Immunotherapy for NSCLC: A Narrative Review. PMID 42512424 · Cancers (Basel) · 2026-Jul-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
First Measurement: Proactively Sparing the Immune System During SBRT to Early-Stage Lung Cancer-A Randomized Phase II Study. PMID 42486309 · Int J Radiat Oncol Biol Phys · 2026-Jul-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
High-dose chemotherapy followed by autologous stem-cell transplantation versus non-myeloablative consolidation in primary CNS lymphoma (MATRix/IELSG43): a randomised phase 3 trial. PMID 42486133 · Lancet · 2026-Jul-22 主要研究目的为安全性/毒性或卫生经济学,未见合格 time-to-event 疗效终点。
H S B
严格 v3 独有 excludedsafety_or_economic_primary_endpoint pending 0 Figure · 0 Panel · risk -
Technical Aspects of Pancreatectomy in the Alliance A021501 Multicenter Clinical Trial of Neoadjuvant Therapy for Pancreatic Cancer: Surgical and Pathologic Documentation. PMID 42485590 · JCO Oncol Pract · 2026-Jul-22 仅有 Phase I/II 证据,未达到确证性随机试验标准。
H B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Utilizing machine learning to identify multimodal signatures for patients who would benefit from the addition of tremelimumab to durvalumab and chemotherapy (TRIDENT). PMID 42485106 · Clin Cancer Res · 2026-Jul-22 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Extent of Lymphadenectomy in Esophageal Cancer Surgery: Unresolved Issues in Prophylactic 3-Field Dissection. PMID 42482330 · J Chest Surg · 2026-Jul-22 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Preoperative single-dose systemic steroid in major head and neck surgery (J-SUPPORT 2002, PreSte-HN Study): a phase III, placebo-controlled, randomized, double-blind study. PMID 42479256 · Int J Clin Oncol · 2026-Jul-21 The study meets criteria for oncology, human, randomized, phase III, drug intervention, and original result. However, it does not include a primary or key secondary time-to-event efficacy endpoint as defined (e.g., OS, PFS, DFS, HR, Kaplan-Meier), so it is ineligible.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and safety of cetuximab-irinotecan rechallenge versus regorafenib in ras wild-type metastatic colorectal cancer: a single-center exploratory randomized trial. PMID 42477619 · BMC Cancer · 2026-Jul-21 The study is a randomized, drug-intervention oncology trial with a time-to-event primary endpoint (PFS). However, it is explicitly described as an 'exploratory randomized trial' and its phase is not stated as Phase III/IIIb or Phase II/III in the abstract. The eligibility criteria require explicit establishment of Phase III/IIIb or Phase II/III status, which is not met here. The study is also described as exploratory and of small sample size (n=68), further suggesting it is not a definitive trial.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
KRAS G12C-Targeted Therapy in Non-Small Cell Lung Cancer: From Resistant Salvage to Potential First-Line Backbone. PMID 42511798 · Int J Mol Sci · 2026-Jul-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Patient-reported Outcomes After Prostate Stereotactic Body Radiotherapy at 5 yr: Results from the PACE-B Trial. PMID 42476886 · Eur Urol · 2026-Jul-20 The report is from a Phase 3 randomized trial in oncology (prostate cancer) but focuses on patient-reported outcomes (quality-of-life/safety) after radiotherapy, which is a non-drug intervention. It does not report a primary or key secondary time-to-event efficacy endpoint such as OS, PFS, DFS, or any Kaplan-Meier/HR analysis.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Strengthening awareness and community resources for early detection of lung cancer through navigation guided screening in American Indian/Alaska Native clinics (SACRED LUNGS): Study protocol. PMID 42476254 · Contemp Clin Trials · 2026-Jul-20 方案论文未报告临床试验结果。
H B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Optimizing prostate biopsy decision making - (MUSIC-screen): A 1:1 randomized controlled trial comparing micro-ultrasound versus multiparametric magnetic resonance imaging for prostate cancer diagnosis. PMID 42476253 · Contemp Clin Trials · 2026-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Adjuvant aspirin for colorectal cancer with PIK3CA-mutated and COX-2 overexpressed tumours: the ASCOLT translational research study and meta-analysis. PMID 42475879 · EBioMedicine · 2026-Jul-20 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
First-Line Immunotherapy Versus Chemotherapy in MSI-H/dMMR Metastatic Colorectal Cancer: A Systematic Review and Meta-Analysis of Phase III Studies. PMID 42474934 · J Gastrointest Cancer · 2026-Jul-20 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Deucravacitinib in Active Psoriatic Arthritis: Efficacy and Safety up to 52 Weeks From the Randomized, Double-Blind, Phase 3 POETYK PsA-2 Trial. PMID 42473780 · Arthritis Rheumatol · 2026-Jul-20 The study is a Phase 3 randomized trial of a drug (deucravacitinib) with primary results, but it is for psoriatic arthritis (not a human malignant neoplasm) and its primary/secondary endpoints are response rates (ACR20, HAQ-DI, etc.), not time-to-event outcomes like OS, PFS, DFS, EFS, RFS, TTP, or Kaplan-Meier/HR analyses.
H B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Treatment Effect Reanalysis of the Randomized Individual Screening Trial of Innovative Glioblastoma Therapy in Newly Diagnosed Glioblastoma With External Control Data. PMID 42172567 · J Clin Oncol · 2026-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Survival Analysis of the WSG TP-II Trial: Neoadjuvant Trastuzumab and Pertuzumab Plus Endocrine Therapy Versus Chemotherapy in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer. PMID 42150145 · J Clin Oncol · 2026-Jul-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Minimal incision-assisted endoscopic versus conventional open breast-conserving surgery: A multicentre randomized clinical trial. PMID 42497645 · Breast · 2026-Jul-19 The study is a phase III randomized controlled trial in oncology (breast cancer), but it compares surgical techniques (minimal incision-assisted endoscopic vs. conventional open breast-conserving surgery) and does not involve a drug-containing intervention. The primary and secondary endpoints are patient-reported outcomes (scar satisfaction, QoL) and surgical metrics, not time-to-event efficacy endpoints (OS, PFS, DFS, EFS, RFS, TTP, Kaplan-Meier, or HR).
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Eltrombopag Added to Standard Immunosuppressive Treatment as Front-Line Therapy for Severe Aplastic Anemia: Long-Term Outcomes of the Phase-3 Randomized Superiority EBMT-SAAWP RACE Study. PMID 42472670 · Am J Hematol · 2026-Jul-19 The study is a randomized Phase III trial with a drug intervention (eltrombopag) and time-to-event endpoints (OS, DFS, EFS), but it is for severe aplastic anemia, a non-oncology hematologic disorder, not a malignant neoplasm.
H S B
严格 v3 独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
OPTIM: a randomized phase II trial of nivolumab followed by nivolumab-ipilimumab or docetaxel at progression in recurrent/metastatic squamous cell carcinoma of the head and neck (OPTIM; AIO-KHT-0117). PMID 42471483 · Br J Cancer · 2026-Jul-18 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Milk of magnesia in enhanced recovery after surgery for preventing postoperative ileus after hysterectomy: randomized controlled trial. PMID 42470487 · Support Care Cancer · 2026-Jul-18 The study is a randomized trial in an oncology population but does not meet key eligibility criteria: the intervention is not an anticancer drug (milk of magnesia), and the endpoints are not time-to-event oncology efficacy endpoints. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A clinical study on fall risk assessment and preventive nursing in older adults with non-Hodgkin's lymphoma undergoing chemotherapy-a randomized controlled trial. PMID 42470465 · Support Care Cancer · 2026-Jul-18 The record describes a randomized trial in oncology patients receiving chemotherapy, but the primary endpoint is fall incidence, not a time-to-event efficacy endpoint (like OS or PFS). The trial phase is not explicitly stated as Phase III/IIIb or Phase II/III. Therefore, it does not meet the eligibility criteria for a Kaplan-Meier digitization cohort focused on drug efficacy time-to-event outcomes.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer. PMID 42464196 · BMC Cancer · 2026-Jul-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition. PMID 42012456 · Clin Cancer Res · 2026-Jul-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Gemcitabine plus Nivolumab with Carboplatin or Oxaliplatin in Cisplatin-Ineligible Patients with Metastatic Urothelial Carcinoma: A Randomized Phase II Trial. PMID 42001507 · Clin Cancer Res · 2026-Jul-17 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Use of ctDNA in Older Women with ER+ Breast Cancer to Facilitate Surgical De-escalation: A Prospective, Hybrid-Decentralized Trial with Correlative Studies. PMID 41854411 · Clin Cancer Res · 2026-Jul-17 The record is a prospective, single-arm trial (n=43) of primary endocrine therapy (pET) with correlative ctDNA analysis. It is not a randomized trial, does not involve a drug-containing intervention arm compared to another arm, and is not Phase III or Phase II/III. Therefore, it does not meet the core eligibility criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Robot-assisted versus open pancreatoduodenectomy for cancer in the pancreatic head (DIPLOMA-2x2): study protocol for an international multicentre patient- and assessor-blinded randomized controlled non-inferiority trial. PMID 42464359 · Trials · 2026-Jul-16 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Effectiveness of silver diamine fluoride in preventing radiation-induced caries: A pilot study. PMID 42461172 · J Am Dent Assoc · 2026-Jul-16 The study is a randomized, placebo-controlled trial in oncology (prevention of radiation-induced caries in head and neck cancer patients). However, the intervention (silver diamine fluoride) is a topical preventive dental agent, not a drug-containing anticancer intervention. The primary endpoint is caries increment (a count/surfaces outcome), not a time-to-event endpoint like OS or PFS. Therefore, it does not meet the criteria for inclusion in the oncology Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of Obinutuzumab in Active Systemic Lupus Erythematosus. PMID 41789864 · N Engl J Med · 2026-Jul-16 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of Adding Immune Checkpoint Inhibitors to Neoadjuvant Chemotherapy on pCR and Tumor Downstaging in Resectable Gastric Cancer: A Meta-Analysis. PMID 42512335 · Cancers (Basel) · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Psychometric Evaluation of the PRO-CTCAE Average Composite Score: Reliability, Responsiveness, Known-Groups Validity, and Sensitivity to Group Differences. PMID 42512331 · Cancers (Basel) · 2026-Jul-15 The record is a psychometric validation study of the PRO-CTCAE Average Composite Score. While it uses data from a Phase III randomized trial (COMET-2), the report's primary purpose is to evaluate the measurement properties of a patient-reported outcome instrument, not to present the trial's efficacy results (e.g., OS, PFS, HR). Therefore, it does not meet the criteria for an original formal-result report of a drug-containing intervention with a primary/key secondary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Recurrence Score® gene group components and outcomes in the RxPONDER trial (SWOG S1007). PMID 42458791 · J Natl Cancer Inst · 2026-Jul-15 This is an original report of a randomized trial (RxPONDER) with a drug intervention (endocrine therapy ± chemotherapy) and a time-to-event endpoint (IDFS). However, it is not a primary or key secondary result report for the overall trial efficacy. The analysis is a pre-specified subgroup/biomarker analysis focusing on gene expression components and disparities by ethnicity, not the primary trial outcome. The phase is not explicitly stated in the provided metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Asciminib as first-line therapy in chronic myeloid leukemia: a systematic review. PMID 42458108 · Blood Res · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Novel BCG Combination or Modified BCG Regimens in BCG-Naïve High-risk Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis. PMID 42457481 · Eur Urol Focus · 2026-Jul-15 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
S B
严格 v3 独有 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Advanced and Salvage Techniques for Difficult Biliary Cannulation in ERCP: A Randomized Trial of Outcomes and Efficacy. PMID 42456983 · Gastrointest Endosc · 2026-Jul-15 The record is not an oncology Kaplan-Meier digitization cohort eligible study. It is a randomized trial in gastroenterology evaluating procedural techniques, not a drug intervention for human malignant neoplasm with a primary time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dose-escalated versus Standard Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer: 9-year Results of a Randomized Phase 2 Trial. PMID 42456783 · Int J Radiat Oncol Biol Phys · 2026-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Clinical Study on the Prevention of High-Risk Pulmonary Nodule Progression With Yifei Sanjie Pill: Protocol for a Multicenter Randomized Controlled Trial. PMID 42456132 · JMIR Res Protoc · 2026-Jul-15 The record is a protocol for a randomized, placebo-controlled trial. While it meets criteria for oncology, human, randomized, drug intervention, and a time-to-event primary endpoint, it is explicitly a protocol without reported results. Furthermore, the trial phase is not specified as Phase III/IIIb or Phase II/III, which is a required eligibility criterion. Therefore, it is excluded.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Surgical Outcomes of Perioperative Toripalimab in Stage III Resectable Non-Small Cell Lung Cancer: Post Hoc Analysis of the Neotorch Randomized Clinical Trial. PMID 42455561 · JAMA Surg · 2026-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
S B
严格 v3 独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Combining VEGFR tyrosine kinase inhibitors and PD-1/PD-L1 inhibitors versus VEGFR tyrosine kinase inhibitors monotherapy in renal cell carcinoma: a target trial emulation. PMID 42428070 · medRxiv · 2026-Jul-15 The record is an observational cohort study using target trial emulation with propensity score matching, not a randomized Phase III trial. Although it involves oncology, human patients, drug interventions, and time-to-event endpoints (OS), the lack of randomization and confirmed Phase III/IIIb or Phase II/III status makes it ineligible.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Phase III, Randomized, Double-Blind, Active-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Tegoprazan for the Prevention of Peptic Ulcer in Patients on Continuous Long-Term Treatment with Nonsteroidal Anti-Inflammatory Drugs. PMID 42325011 · Gut Liver · 2026-Jul-15 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term benefit from adjuvant tamoxifen therapy for ER+ HER2- breast cancer by PR positivity. PMID 41787605 · Int J Cancer · 2026-Jul-15 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
B
仅广召回影子组 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Comparing the effectiveness of prostate cancer screening protocols: European Association of Urology- and European Randomized Study of Screening for Prostate Cancer-based strategies. PMID 41741956 · Int J Cancer · 2026-Jul-15 Study is a microsimulation modeling analysis comparing prostate cancer screening strategies; it is not a Phase III/IIIb or Phase II/III randomized trial of a drug intervention with a primary time-to-event efficacy endpoint (e.g., OS, PFS).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -